| Bid | 0.31 |
| Market Cap | 3.19M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -3.8 |
| PE Ratio (ttm) | -0.08 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.35 |
| Volume | 794,744 |
| Avg. Volume (20D) | 2,040,916 |
| Open | 0.35 |
| Previous Close | 0.34 |
| Day's Range | 0.28 - 0.36 |
| 52-Week Range | 0.22 - 2.27 |
| Beta | undefined |
About PTPI
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vac...
Analyst Forecast
According to 1 analyst ratings, the average rating for PTPI stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 1157.47% from the latest price.
3 years ago · investorplace.com
Short Squeeze Stocks: ISIG, RELI and 3 Others Experts Think Are Ready to PopThese five top short squeeze stocks are among the top speculative plays investors and traders are watching in today's market. The post Short Squeeze Stocks: ISIG, RELI and 3 Others Experts Think Are R...
